Evidence map›Paper›PMID 38543083›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

An Inulin-Type Fructan CP-A from

Jiangtao Zhou, Deyun Li, Jiajing Wang, Zhuoyang Cheng, Changjian Wang, Xuepeng Zhang, Xiexin Xu, Jianping Gao

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Frontiers in pharmacology · 2026
    Article
  4. Article
  5. Alleviation of LPS-induced Endothelial Injury due to GHRH Antagonist Treatment.International journal of peptide research and therapeutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jiangtao ZhouSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Deyun LiSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Jiajing WangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Zhuoyang ChengSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Changjian WangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Xuepeng ZhangSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Xiexin XuSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Jianping GaoSchool of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
Shanxi Medical University · CN

Funding

National Key Research and Development Program of China 2019YFC1710800National Natural Science Foundation of China 81904031Natural Science Foundation of Shanxi Province 201901D211325Science Research Start-up Fund for Doctor of Shanxi Medical University XD1802
6 · The paper itself

Abstract

Intestinal mucositis (IM) is a common adverse effect of chemotherapy, limiting its clinical application.

Indexed as

ERK/MLCK/MLC2 signaling pathwayinflammationintestinal microbiotaintestinal mucositisinulin-type fructan CP-Amucosal barrier

Identifiers

PMID38543083
PMCPMC10975959
OpenAlexW4392168615

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.